Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PLx Pharma Inc.PLXP · Entity 129056 | 10% owner | November 18, 2020 | March 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PLx Pharma Inc.
Report date November 18, 2020 · Filed March 16, 2021
Jointly reported with Level One Partners, LLC, Hardie Molly G.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 1,320,306 |
Reported balance
Holding disclosure · report date 2020-11-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,320,306 F1: Level One Partners, LLC (the "Reporting Person") is owned by Robert D. Hardie ("Mr. Hardie") and Molly G. Hardie ("Ms. Hardie"), who are married. Mr. Hardie is the manager of the Reporting Person and also holds shares of PLx Pharma Inc. (the "Company") individually. F2: As of the date of this report, the Reporting Person holds 1,320,306 shares of Common Stock, $.001 par value per share (the "Common Stock") of the Company, and Mr. Hardie holds 875,000 shares of Common Stock of the Company. Pursuant to 17 CFR Section 240.16a-1(a)(2), Ms. Hardie's beneficial ownership is limited to her pecuniary interest, if any, in such securities. |
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 875,000 |
Reported balance
Holding disclosure · report date 2020-11-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 875,000 F2: As of the date of this report, the Reporting Person holds 1,320,306 shares of Common Stock, $.001 par value per share (the "Common Stock") of the Company, and Mr. Hardie holds 875,000 shares of Common Stock of the Company. Pursuant to 17 CFR Section 240.16a-1(a)(2), Ms. Hardie's beneficial ownership is limited to her pecuniary interest, if any, in such securities. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2025-11-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-11-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: As of the date of this report, the Reporting Person holds warrants to purchase 1,452,337 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Level One Partners, LLC (the "Reporting Person") is owned by Robert D. Hardie ("Mr. Hardie") and Molly G. Hardie ("Ms. Hardie"), who are married. Mr. Hardie is the manager of the Reporting Person and also holds shares of PLx Pharma Inc. (the "Company") individually.
F2: As of the date of this report, the Reporting Person holds 1,320,306 shares of Common Stock, $.001 par value per share (the "Common Stock") of the Company, and Mr. Hardie holds 875,000 shares of Common Stock of the Company. Pursuant to 17 CFR Section 240.16a-1(a)(2), Ms. Hardie's beneficial ownership is limited to her pecuniary interest, if any, in such securities.
F3: As of the date of this report, the Reporting Person holds warrants to purchase 1,452,337 shares of Common Stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acumen Pharmaceuticals, Inc.
Report date July 06, 2021 · Filed July 08, 2021
Section 16 reporting ended · disclosed 2021-07-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,040,193 |
Reported balance
After 2021-07-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-07-06 · Conversion · Acquired 2,950,484 · Balance 3,040,193 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,352,693 |
Reported balance
After 2021-07-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-07-06 · Purchase · Acquired 312,500 · Balance 3,352,693 F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 657,985 |
Reported balance
After 2021-07-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-07-06 · Conversion · Acquired 657,985 · Balance 657,985 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-07-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-06 · Conversion · Disposed 1,634,515 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-07-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-06 · Conversion · Disposed 1,315,969 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-07-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-06 · Conversion · Disposed 657,985 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries B Preferred Stock · Derivative | 657,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · derivative · entry 6 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 657,985 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries B Preferred Stock · Derivative | 1,315,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · derivative · entry 5 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,315,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries A-1 Preferred Stock · Derivative | 1,634,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · derivative · entry 4 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,634,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 657,985 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · nonDerivative · entry 3 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 657,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · nonDerivative · entry 2 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,352,693 F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:15 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 2,950,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046028 · doc4.xml · nonDerivative · entry 1 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,040,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries B Preferred Stock · Derivative | 2,076,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046027 · doc4.xml · derivative · entry 5 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,076,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionSeries A-1 Preferred Stock · Derivative | 1,124,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046027 · doc4.xml · derivative · entry 4 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,124,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | PurchaseCommon Stock | 750,000 | $16.00 | $12,000,000.00 |
DisclosureSEC source: 0001209191-21-046027 · doc4.xml · nonDerivative · entry 3 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,951,156 F4 · ownership.nature: Consists of 375,000 shares of common stock held by H7 Holdings LLC, and 375,000 shares of common stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 2,076,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046027 · doc4.xml · nonDerivative · entry 2 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 3,201,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.nature: Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 18:14 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | ConversionCommon Stock | 1,124,830 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-046027 · doc4.xml · nonDerivative · entry 1 Hardie Robert D. · CIK 0001804350 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,124,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.